Insights for optimized selection and implementation of COAs and eCOA in clinical trials
Clinical Outcome Assessments (COAs) are the IP of their respective developers and are thus protected by national and international copyright laws unless otherwise indicated. In this whitepaper, we cover the prerequisites for controlled use of COAs and provide suggestions for streamlining the licensing process, which can be complex and typically involves multiple parties.
Coming up soonThis whitepaper developed in collaboration with ICON plc describes the sequence of events involved in the development cycle of eCOA (COA licensing, translation, eMigration, User Acceptance Testing) and presents a recommended approach to planning and implementing eCOA to mitigate the risks of delaying the study start up.
Read the whitepaper